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Introduction 
 Obsessive-compulsive disorder (OCD) is a common psychiatric disorder, creating 
harmful effects on social and occupational functioning for OCD patients..  OCD is characterized 
by “persistent thoughts (obsessions) and repetitive ritualistic behaviors (compulsions).”1  
Common obsessions include contamination fears and forbidden sexual thoughts, while common 
compulsions include cleaning and counting rituals.2  Many patients experience OCD symptoms 
beginning in childhood, leading to a chronic and debilitating disease when left untreated.2  
Currently, OCD has an estimated lifetime prevalence of 2%, affecting both genders equally.1  In 
1990 (the most recent year for which data is available), it was estimated that the total costs of 
OCD were 8.4 billion dollars;3 this has likely gone up tremendously in the past two decades.  In 
addition, from the years 1995-1996, 2,043 individuals from a 1,728,480 person health 
maintenance organization (HMO) had the clinical diagnosis of OCD.4 
 Currently, the exact cause of OCD is unknown, however at this time it has been thought 
that the cause is due to a combination of genetic and environmental factors.5  With many studies 
underway, “recent evidence highlights an abrupt onset of OCD symptoms in some cases in the 
context of group A beta-hemolytic streptococcal (GABHS) infection.”5  With specific disease 
causes largely unknown, treatment is often generalized in nature.5  Common conventional 
treatments are pharmacotherapy with high-dose serotonergic antidepressant medications or 
behavioral psychotherapy, or a combination of the two5.  Despite treatment advances, it is 
estimated that current treatments provide a “mean of 40% to 60% symptom reduction in half of 
the patients,” leaving many with ongoing symptoms.1  In addition, 10% of patients will be 
plagued with severe, treatment-refractory OCD.1  For a portion of treatment-refractory patients, 
neurosurgical treatment may serve as a more effective, long-lasting resort.   
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 Deep brain stimulation (DBS) is a neurosurgical treatment in which electrodes are 
implanted in specific areas of the brain, selected according to the type of symptoms being 
targeted.1  The electrodes send out electrical impulses to the neuronal tissue of the target brain 
location.1  Although not widely used, DBS is promising in that it may provide an alternate 
treatment option for refractory OCD, with successful outcomes having already been shown. 
Objective 
The objective of this systematic review is to determine whether or not deep brain stimulation 
(DBS) is an effective treatment for refractory obsessive compulsive disorder (OCD) in adults. 
Methods 
 All three studies included in this review met the following criteria.  The population 
included adults at least 18 years of age with treatment refractory OCD and a minimum score of 
25 on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS).1,6,7  The Abelson et al6 and 
Denys et al1 studies were both double-blind, sham-controlled randomized controlled trials, while 
the third study used, Goodman et al7, was a blinded, staggered-onset randomized controlled trial. 
The intervention used was deep brain stimulation of the following areas of the brain: ventral 
anterior limb of the internal capsule and adjacent ventral striatum (Goodman et al7), nucleus 
accumbens of the ventral striatum (Denys et al1), and the anterior limb of each internal capsule 
(Abelson et al6).  All studies reviewed compared the treatment group to a control group which 
received random “sham stimulation.”1,6,7  The main outcome measured in each of the studies was 
the severity of OCD symptoms based on changes from baseline in OCD symptoms using Y-
BOCS.1,6,7  This outcome qualifies as patient oriented evidence that matters (POEM). 
 The author searched for articles using PubMed, Medline and Cochrane Databases using 
the keywords “obsessive-compulsive disorder,” “refractory,” and “deep brain stimulation.”  All 
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articles selected were published in English, in peer-reviewed journals.  The inclusion criteria 
were studies that were randomized controlled trials published after 1996 and that had patient-
oriented outcomes (POEMS).  The exclusion criteria were articles that included patients under 
the age of 18 years old, patients that were diagnosed with substance abuse, or lastly, patients that 
were diagnosed with psychoses.  The statistics included were p-values and Numbers Needed to 
Treat (NNT). 
Table 1: Demographics and Characteristics of Included Studies 
Study Type # 
Pts 
Age Inclusion Criteria Exclusion Criteria W/D Interventions 
Denys et 
al1 
Double-
blind, 
sham-
controlled 
RTC 
16 21-
59 
Pts. diagnosed with primary 
OCD using DSM-IV, ≥28 on 
Y-BOCS, >5 year history of 
OCD, exp substantial 
functional impairment 
according to DSM-IV 
Criterion C, GAF score of 45 
or less, experienced 
refractoriness to therapy, 
partook in at least 1 CBR for 
≥16 sessions 
Pts. who had 
clinically significant 
DSM-IV comorbid 
diagnoses, who had 
severe personality 
disorders, who had 
clinically significant 
and unstable 
neurologic or 
medical illnesses 
2 Treatment with 
bilateral DBS of the 
nucleus accumbens 
Abelson 
et al6 
Double-
blind, 
sham-
controlled 
RCT 
4 27-
52 
Patients who had a Y-BOCS 
scale ≥25, a GAF score less 
than 44, who had multiple 
unsuccessful treatment 
attempts with anti-obsessional 
mediation, who partook in 
medication trials on at least 
four anti-obsessional 
medications proven effective, 
who had exposure to various 
medication combinations, who 
received 12 weeks of CBT 
w/o meaningful benefit and 
who were in “good”  general 
health 
Pts. who had no 
history of psychosis 
and who has no 
current substance 
abuse 
N/A Quadripolar 
stimulating 
electrodes placed 
stereotaxically in the 
anterior limb of each 
internal capsule; 
connected via 
subcutaneous wires 
to implantable pulse 
generators placed in 
the subclavicular 
area 
Goodman 
et al7 
Blinded, 
staggered-
onset RCT 
6 27-
52 
Patients who met DSM-IV 
score for OCD, ≥28 on Y-
BOCS, 5-year history of 
treatment refractory OCD 
symptoms since age 18, 
partook in an adequate trial of 
clomipramine, and at least two 
SSRIs (fluoxetine, 
fluvoxamine, citalopram, 
sertraline, paroxetine), with 
addition of one or more of the 
aforementioned drugs with at 
least two of the following: 
clonazepam, haloperidol, 
Patients who had a 
lifetime diagnosis of 
psychosis or bipolar 
disorder, who had 
chemical abuse 
issues within the 
previous six months, 
who had a primary 
diagnosis of 
depression within the 
previous year, who 
had a current DSM-
IV Axis II diagnosis 
from cluster A, and 
N/A Treatment with DBS 
electrode arrays 
placed bilaterally in 
an area spanning the 
ventral anterior limb 
of the internal 
capsule and adjacent 
ventral striatum. 
 Luczyszyn, OCD & Deep Brain Stimulation   4	  
risperidone, olanzapine or 
gabapentin and who partook 
in an adequate trial of CBT 
who had the presence 
of brain pathology 
 
   
Outcomes Measured 
 Each article’s primary outcome measured was OCD symptom severity based on the Yale-
Brown Obsessive Compulsive Scale (Y-BOCS).  The Y-BOCS is a clinician rated scale with 10 
different items scored from either 0 (no symptoms) to 40 (severe symptoms).8  This scale has 
questions dealing with both obsessions and compulsions.  The scores then represent a stage of 
OCD, with a score of 0-7 indicating subclinical OCD, 8-15 as mild OCD, 16-23 as moderate 
OCD, 24-31 as severe OCD and 32-40 as extreme OCD.8  Goodman et al7 specified that each Y-
BOCS assessment was conducted by either the principle investigator, a clinical psychiatrist, or a 
psychiatric research nurse, Denys et al1 specified that assessments were conducted by a trained 
investigator; however, Abelson et al6 failed to specify who conducted the assessments. 
 Each study also assessed secondary outcome measures such as the Hamilton Depression 
Scale (HAM-D) and the Hamilton Anxiety Scale (HAM-A).  This review is limited to results 
based on the severity of OCD symptoms using the Y-BOCS assessment. 
Results 
 In Goodman et al7, a responder was defined as a subject with both a 35% reduction in 
score from baseline and an actual Y-BOCS score of 16 or less at the time of assessment.  This 
definition of a responder created a set of dichotomous data; responders and non-responders.  Y-
BOCS scores were also analyzed as continuous data with repeated-measure analysis of variance 
(ANOVA).7  All six of the study’s participants were implanted with neuro-stimulation.  At one 
month post-implantation, three of the subjects received active DBS while the remainder of the 
subjects received sham stimulation.7  At two months, those receiving sham stimulation were 
converted to active DBS.7  At this two month mark, all study participants were receiving active 
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DBS7.  All of the above actions were conducted in a double blind setting.  Graph 17 demonstrates 
Y-BOCS score progression over time, with 1A demonstrating the scores of the early DBS 
activation group and 1B demonstrating the scores of the late DBS activation group.  It is 
important to note that unbeknownst to subject 1 or the treatment team, subject 1’s right-sided 
battery was depleted between 11 and 12 months.7  The ineffective DBS battery led to an OCD 
exacerbation (black triangle) and then a subsequent normalization (gray triangle) shortly after 
battery replacement7.    
Graph 1. Y-BOCS Score vs. Time Since DBS Surgery 
 
a. This graph comes directly from Goodman et al7 
 
 Visual inspection of Graph 17 demonstrates very little reduction in Y-BOCS scores with 
the control subjects (sham stimulation) and an obvious varying decrease in Y-BOCS scores upon 
DBS activation.  Overall, there was a significant decrease in Y-BOCS scores over time, with a 
decrease of 15.67 ± 11.60 after 12 months of DBS activation (p-value of 0.0392 using 
ANOVA).7  Four of the six participants were classified as responders.  The RBI and ABI were 
calculated to be 67% with NNT being 2 patients, as demonstrated in Table 27.  
Table 2. Key Values from the Three RCT’s Being Reviewed 
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 p-value CER EER RBI ABI NNT 
Goodman et 
al7 
0.0392 0% 67% 67% 67% 2 patients 
Abelson et 
al6 
N/A 0% 25% 25% 25% 4 patients 
Denys et al1 0.004 0% 56% 56% 56% 2 patients 
 
 Overall, the Goodman et al7 study was relatively safe, with all original participants 
completing the trial in its totality.  Compliance was not specifically noted, however it is assumed 
that actual DBS compliance was 100% being that stimulators were neuro-surgically implanted, 
with no indication that the DBS stimulation was removed throughout the trial.  It is important to 
note that unexpected adverse events did not occur in response to implantation, such as seizures or 
cerebral hemorrhage.7  Table 3 demonstrates the adverse events of stimulation observed 
throughout the trial.  Only one serious event was noted upon which hospitalization was required7.   
Table 3. Goodman et al7 Adverse Events 
Adverse Event N % Affected 
Contralateral smile w/ mirth 5 83.333% 
Hypomania 4 66.667% 
Serious AE (unspecified, but 
required hospitalization) 
1 16.667% 
Bipolar Disorder 0 0.000% 
 
 In Abelson et al6, a responder was defined as one who experienced ≥ 35% decline in Y-
BOCS score from baseline.  According to Abelson et al6, “the literature indicates that the anterior 
capsulotomy produces a 35% improvement in OCD symptoms in about 45% of patients who 
receive the operation,”6 hence the justification of this study’s responder definition.   It is 
important to note that an exploratory phase of the study was performed prior to the double-blind 
phase.  During this phase, which was performed at a General Clinical Research Center, a range 
of stimulation parameters were tested to determine tolerability and effects of stimulation.6  This 
exploratory phase helped determine evidence of stimulation benefit and/or “maximum levels of 
undetectable sitmulation.”6   
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 In the double-blind phase of this study (the only phase being analyzed in this review), one 
out of four subjects were classified as responders. Throughout the double-blind study, there were 
a total of eight ON periods (active stimulation) and eight OFF periods (sham stimulation).6  As 
seen in Table 3, Subject 3 (responder) demonstrated a 67% reduction in Y-BOCS score from 
baseline during the ON periods, while only demonstrating a 23% reduction in Y-BOCS score 
from baseline during the OFF periods.6  Subject 2 (non-responder) demonstrated a 13% change 
from baseline during ON stimulation and a 19% change from baseline during OFF stimulation, 
demonstrating some sort of placebo effect.6 The mean reduction from baseline in Y-BOCS with 
stimulators ON was 19.8% (SD 29.8), while the mean with stimulators OFF was 10.5% (SD 
17.8).6  As Table 2 demonstrates, the NNT was 4 patients (the entire subject population for this 
study).    
Table 3. Abelson et al6 Subject Characteristics and Mean Y-BOCS Scores during Double Blind 
Testing 
 Subject 1 Subject 2 Subject 3 Subject 4 
Age 52 27 48 34 
OCD Duration (years) 46 11 16 17 
Gender Male Female Female Male 
Symptoms Repeating, reentering, 
order/symmetry, 
counting 
Intrusive images (of 
sex, violence), mental 
arranging, counting, 
cleaning 
Contamination, cleaning, 
checking/repeating, 
symmetry 
Repeating, 
“just right” 
behavior 
Baseline Y-BOCS 
Score 
39 36 30 26 
Mean (% decline in 
Y-BOCS from 
baseline)—ON 
37.5 (4) 31.5 (13) 10 (67) 27 (-4) 
Mean (% decline in 
Y-BOCS from  
baseline)a—OFF 
39 (0) 29 (19) 23 (23) 26 (0) 
Side Effects of 
Stimulation 
None Throbbing, buzzing, 
nausea, diarrhea 
Tingling Jaw sensations 
a. All information from this table was taken directly from Abelson et al6 
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 Also seen in Table 3 are the DBS side effects that each of the four subjects experienced 
in the Abelson et al6 study.  Somatic symptoms such as throbbing, buzzing, nausea, diarrhea, 
tingling and jaw sensations were noted.6  Overall, no evidence of cognitive impairment or 
personality changes were noted from either patients or family members.6 Despite side effects, 
there was a 100% retention rate of study subjects throughout the double-blind phase of the trial.6 
 Similar to Abelson et al6, in the study performed by Denys et al1, responders were 
defined as those with a ≥ 35% decrease in Y-BOCS score from baseline.  Prior to the double-
blind, sham controlled phase of the Denys et al1 study, there was an open stimulation phase.  
This open DBS phase lasted 8 months, with subjects being evaluated every 2 weeks for OCD 
symptom severity and optimal stimulation parameters.1  At the conclusion of the 8 months, the 
double-blind, sham-controlled phase began.  Subjects were randomly assigned two periods of 2 
weeks each, with active stimulation in one period and sham stimulation during the other period.1  
Subjects were assessed at baseline, after their first 2 week period of either active or sham 
stimulation, and then after the second 2 week period.1  It should be noted that two subjects 
refused to enter the double-blind, sham controlled crossover phase of experimentation.  One 
subject feared losing the positive effects of open-phase DBS and the other was dissatisfied with 
the overall effects of DBS.1  No further analysis was performed on these subjects.  Overall there 
was a decrease in Y-BOCS score from baseline throughout the 8-month open stimulation phase, 
as demonstrated in Table 4.  Mean scores during ON/OFF periods, as well as changes between 
ON and OFF periods during the double-blind phase were calculated, as demonstrated in Table 4 
as well. The mean Y-BOCS score decrease from sham to active stimulation in the entire sample 
of 14 subjects was 8.8 points (SD of 9.1; 95% CI, 3.6-14.1; P.003).1  After a correction for 
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period effects, stimulation “caused a substantial (mean, 8.3 [2.3] points [25%]) and statistically 
significant (P=.004) reduction in the Y-BOCS total score during the double-blind phase.”1   
 As seen in Table 2, the NNT was calculated to be 2 patients.  It is important to note that 
there were 9 responders out of 16 total subjects; however, the number of responders was 
calculated at the conclusion of the entire 21 month study.  The double-blind crossover phase was 
followed by a 12 month maintenance phase, in which all participating subjects received active 
stimulation.1  Also crucial to the results is the fact that for all but 4 subjects, the blinded status of 
the stimulator was lifted due to abrupt worsening of symptoms.1 
Table 4. Denys et al1 Changes in OCD Symptom Severity During Double-Blind Crossover 
Period 
Start of Crossover Period 
 
Change Between 
Weeks 1-2 and 
Weeks 3-4 
 
Variable Mean 
Baseline 
(SD) 
After 8 mos of 
Stimulation 
(SD) 
Weeks 1-2 Weeks 3-4 Mean (SD) 
[95% CI] 
P 
Value 
Group 1 (n=6) 
Y-BOCS Total 
Score 
34.2 (3.6) 23.3 (9.9) After 
Stimulation On: 
25.8 (9.3) 
After 
Stimulation Off: 
30.7 (4.5) 
4.9 (7.6) [-
12.9 to 3.2] 
.18 
Group 2 (n=8) 
Y-BOCS Total 
Score 
33.4 (3.6) 18.7 (10.6) After 
Stimulation Off: 
29.5 (11.4) 
After 
Stimulation On: 
17.6 (10.1) 
11.9 (9.3) 
[4.0 to 19.7] 
.009 
a. All information from this table was taken directly from Denys et al1 
 
 In the Denys et al study1, two of the sixteen total subjects refused to enter the double-
blind phase of the study and only completed the open phase.  Out of the remaining fourteen 
subjects, ten individuals requested the blinded status of the stimulation was lifted due to 
worsening of symptoms, as previously stated.  An array of adverse events were reported and 
these can be split into surgery related, device related and stimulation related events.  Issues such 
as infection at the incision site and numbness at the incision site were just a sample of the 
adverse events reported from surgery, with none of these being permanent.1  Feelings of 
electrical current around the neurostimulator and feelings of the neurostimulator in the chest 
were device-related complaints reported by subjects, with some being permanent.1  Lastly, 
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twenty-two different stimulation related effects were reported, with hypomanic symptoms being 
the most common complaint.1  A few of these complaints, such as forgetfulness, were reported to 
be permanent.1 
Discussion 
 Many previous studies have been done concerning the effects of deep brain stimulation 
on movement disorders, such as Parkinson’s Disease.  DBS for Parkinson’s Disease has become 
much more wide-spread and accessible throughout the past decade.9  Contrastingly, DBS and its 
effects on psychiatric disorders, such as OCD, is a much less familiar territory in terms of 
research and practice.  In 2009, the FDA approved the “Medtronic Reclaim DBS therapy,” which 
is “indicated for bilateral stimulation of the anterior limb of the internal capsule” for “severe, 
treatment-resistant obsessive compulsive disorder (OCD).”10  The FDA also issued a warning of 
the potential danger of excessive DBS causing damage to neuronal tissue, which is a truly 
significant concern that all clinicians and patients must take into account.10  The FDA guidelines 
are very specific, indicating DBS only for the anterior limb of the internal capsule, an area of the 
brain not even studied in Goodman et al7.10  Not only are indications for DBS in OCD sparse, but 
so is the availability of such a treatment.  Most DBS procedures for OCD are performed only at 
major academic hospitals in large metropolitan areas.  In addition, Medicare does cover DBS as 
a treatment for OCD; however, many private insurance companies do not.11 
 The limitations to each of the three studies being reviewed are numerous, and much more 
research must be carried out before DBS takes the place of anterior capsulotomy for the 
treatment of refractory OCD.  Currently, anterior capsulotomy is the most prevalent, 
neurosurgical “last-resort” option for this illness and it is with hope that DBS will eventually be 
more successful than invasive capsulotomy.12  Each of the three studies reviewed contained no 
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more than 20 subjects to analyze, a sample size that is significantly small for research and 
statistical analysis purposes.  Also, the desperation of the subjects being studied and the last-
resort context of DBS created a “fertile context for placebo responses.”6  In addition, many of the 
subjects developed a sense of the stimulator being ON vs OFF through a perceived somatic 
sensation.6  This sense could have muffled the blind nature of the studies.  In one study, the 
majority of subjects even refused to allow the blind status to be continued.  Much more focus 
must also be put on finding the optimal stimulation parameters for an individual because this has 
the ability to greatly influence outcome. 
Conclusion 
 The studies reviewed demonstrate inconclusive evidence as to whether or not deep brain 
stimulation (DBS) is an effective treatment for refractory obsessive-compulsive disorder (OCD) 
in adults.  The Goodman et al7 study is the only study that concluded that DBS is a “promising 
therapy of last resort for carefully selected cases of severe and intractable OCD.”7  Denys et al1 
and Abelson et al6 admit to its potential, but are weary of widespread use without intense further 
research.  In the future it would be advantageous to greatly improve the actual stimulator 
engineering in order to dissolve variables such as battery life and function.  Also, more strict 
DBS parameters must be explored before the widespread use of DBS in refractory OCD.  In 
addition, studies comparing anterior capsulotomy to DBS for the treatment of refractory OCD 
would be enlightening to this field of research. 
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